Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
WEST LAFAYETTE, Ind., May 01, 2018 -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at Deutsche Bank’s 43rd Annual Health Care Conference being held at the Intercontinental Hotel Boston on Tuesday, May 8th at 1:35 p.m. EDT.
A live audio webcast of the Company's presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte's website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company's website for 90 days following the conference.
Website Information
Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the “Investors & News” section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic in 2018, where it will be studied in osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Investor Contact:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
